{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:44:30Z","timestamp":1792424670914,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2018,1,22]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Lanthanum (La) is considered to be a non-essential element. La has been\nused for several decades in China to improve yield in plant production and has also been shown to\nhave significant performance enhancing effects in feeding trials on animal husbandry. The estimated\ndietary intake of La in humans is below 150 \u00b5g, which is lower than 10% of the estimated\nlimit of safe and acceptable daily intake.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> The present review is based on literature search in available databases.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Upon ingestion of La as carbonate, the lanthanum ion (La3+) is released in the stomach\nand traps dietary phosphate as insoluble lanthanum phosphate complexes in the gut, thereby inhibiting\nphosphate absorption. Lanthanum carbonate as a drug to lower serum phosphate in endstage\nkidney failure was approved for human use by the US FDA in 2004 and by the EU in 2006. When\nused to treat patients with advanced renal insufficiency, lanthanum carbonate is administered\norally at a dose of maximally 3000 mg per day. The uptake of lanthanum ions from the gut to the\ncirculation is negligible. And few systemic side effects have been recorded upon the use of lanthanum\ncarbonate as a phosphate binding drug, although gastrointestinal discomfort with pain, vomiting\nand diarrhea may occur. Lanthanum carbonate has the potential to chelate to drugs with anionic\ngroups and therapeutic co-administration with lanthanum carbonate may reduce the bioavailibility\nof drugs like tetracyclines, quinolones and levothyroxine.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The findings in this review confirm that lanthanum carbonate is a clinically useful\nphosphate binding drug with few side effects in advanced renal failure.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867324666170509125840","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T07:04:12Z","timestamp":1494399852000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure"],"prefix":"10.2174","volume":"25","author":[{"given":"Jan","family":"Aaseth","sequence":"first","affiliation":[{"name":"Department of Research, Innlandet Hospital Trust, 2380 Brumunddal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Bjorke-Monsen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Biochemistry, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/152285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/152285\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/152285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T10:00:21Z","timestamp":1608890421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/152285\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666170509125840","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}